StockData
Rallybio Corp logo

Rallybio Corp (RLYB) income statement

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.52+0.26 (+1.70%)

Close on Nov 19, 2026Market cap $83.56MP/E 3.4Yield –

Rallybio Corp income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-5580.9%
Net margin
6177.4%
Return on equity, FY2025
-15.0%

Financial strength

Current ratio
28.87
Debt to equity
–
Debt to assets
–
Cash to current liabilities
2762.5%

Valuation

P/E ratio
3.4
Price to sales
192.53
Price to book
0.91
Dividend yield
–

See a number that looks wrong?